Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment | Zendy

Vivian Barry-Hamilton | Zendy; Rhyan Spangler | Zendy; Derek Marshall | Zendy; Scott McCauley | Zendy; Héctor M. Rodrı́guez | Zendy; Miho Oyasu | Zendy; Amanda Mikels | Zendy; Maria Vaysberg | Zendy; Haben Ghermazien | Zendy; Carol Wai | Zendy; Carlos García | Zendy; Arleene C. Velayo | Zendy; Brett Jorgensen | Zendy; D. Biermann | Zendy; D. E. Tsai | Zendy; Jennifer Green | Zendy; Shelly Zaffryar-Eilot | Zendy; Alison K. Holzer | Zendy; Scott Ogg | Zendy; Dung Thai | Zendy; Gera Neufeld | Zendy; Peter Van Vlasselaer | Zendy; Victoria Smith | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment

Author(s) -

Vivian Barry-Hamilton,

Rhyan Spangler,

Derek Marshall,

Scott McCauley,

Héctor M. Rodrı́guez,

Miho Oyasu,

Amanda Mikels,

Maria Vaysberg,

Haben Ghermazien,

Carol Wai,

Carlos García,

Arleene C. Velayo,

Brett Jorgensen,

D. Biermann,

D. E. Tsai,

Jennifer Green,

Shelly Zaffryar-Eilot,

Alison K. Holzer,

Scott Ogg,

Dung Thai,

Gera Neufeld,

Peter Van Vlasselaer,

Victoria Smith

Publication year - 2010

Publication title -

nature medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.536

H-Index - 547

eISSN - 1546-170X

pISSN - 1078-8956

DOI - 10.1038/nm.2208

Subject(s) - lysyl oxidase , desmoplasia , cancer research , tumor microenvironment , fibrosis , pathology , stroma , cancer , transforming growth factor , biology , medicine , extracellular matrix , immunohistochemistry , microbiology and biotechnology , tumor cells

We have identified a new role for the matrix enzyme lysyl oxidase-like-2 (LOXL2) in the creation and maintenance of the pathologic microenvironment of cancer and fibrotic disease. Our analysis of biopsies from human tumors and fibrotic lung and liver tissues revealed an increase in LOXL2 in disease-associated stroma and limited expression in healthy tissues. Targeting LOXL2 with an inhibitory monoclonal antibody (AB0023) was efficacious in both primary and metastatic xenograft models of cancer, as well as in liver and lung fibrosis models. Inhibition of LOXL2 resulted in a marked reduction in activated fibroblasts, desmoplasia and endothelial cells, decreased production of growth factors and cytokines and decreased transforming growth factor-beta (TGF-beta) pathway signaling. AB0023 outperformed the small-molecule lysyl oxidase inhibitor beta-aminoproprionitrile. The efficacy and safety of LOXL2-specific AB0023 represents a new therapeutic approach with broad applicability in oncologic and fibrotic diseases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research